NYSE:JNJ - Johnson & Johnson Stock Price, Price Target & More

Get Started

$121.47 +0.12 (+0.10 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$121.47

Today's Range$121.13 - $122.80

52-Week Range$121.13 - $148.32

Volume4.59 million shs

Average Volume7.49 million shs

Market Capitalization$331.20 billion

P/E Ratio16.64

Dividend Yield2.72%

Beta0.74

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:JNJ

CUSIP47816010

Webwww.jnj.com

Phone732-524-0400

Debt

Debt-to-Equity Ratio0.47

Current Ratio1.58

Quick Ratio1.25

Price-To-Earnings

Trailing P/E Ratio16.64

Forward P/E Ratio14.94

P/E Growth1.89

Sales & Book Value

Annual Sales$76.45 billion

Price / Sales4.26

Cash Flow$9.4090 per share

Price / Cash12.91

Book Value$23.58 per share

Price / Book5.15

Profitability

EPS (Most Recent Fiscal Year)$7.30

Net Income$1.30 billion

Net Margins1.58%

Return on Equity30.65%

Return on Assets13.26%

Miscellaneous

Employees134,000

Outstanding Shares2,682,900,000

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Thursday, April 26th. Stockholders of record on Tuesday, May 29th will be given a dividend of $0.90 per share on Tuesday, June 12th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Friday, May 25th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $0.84. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its quarterly earnings data on Tuesday, April, 17th. The company reported $2.06 EPS for the quarter, beating analysts' consensus estimates of $2.00 by $0.06. The company had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The business's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.83 earnings per share. View Johnson & Johnson's Earnings History.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July, 17th 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY18 earnings guidance on Tuesday, April, 17th. The company provided earnings per share (EPS) guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.10. The company issued revenue guidance of $81.0-81.8 billion, compared to the consensus revenue estimate of $81.18 billion.

What price target have analysts set for JNJ?

20 brokers have issued 1 year target prices for Johnson & Johnson's stock. Their predictions range from $110.00 to $165.00. On average, they anticipate Johnson & Johnson's share price to reach $143.0556 in the next year. View Analyst Ratings for Johnson & Johnson.

What are Wall Street analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

1. According to Zacks Investment Research, "J&J’s sales growth accelerated in the second half of 2017 backed by higher sales in the Pharmaceutical segment and improving performance in Medical Devices. Though quite a few key products in J&J’s portfolio like Remicade and Concerta are facing generic competition, we believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion – can support top-line growth. Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. J&J’s shares have underformed the industry in this year so far. Estimates have risen slightly ahead of Q1 results. J&J has a positive record of earnings surprises in the recent quarters." (4/16/2018)
2. BTIG Research analysts commented, "Present – Starting to Outweigh Macro Tailwinds On Tuesday before market-open, JNJ reported 4Q17 financial results. In- line with our forecasting for the Pharma segment, the Actelion portfolio has begun to significantly disappoint expectations, Remicade erosion is accelerating, and mainstay franchises such as Imbruvica are beginning to moderate growth. The major discussion point we have had with investors is whether our negative Pharma thesis can trump the positive macro factors. We continue to think so, despite tailwinds such as tax reform helping the stock and overall stock market during 2H2017. At the end of the day, Pharma drives over 50% of total profit generation for the company. We reiterate our Sell rating and $110 PT.   We forecast 1Q18 as the peak of recent Pharma growth and expect a mirror image of 2017 for the remainder of the year, whereby growth will moderate significantly into 2H2018: Our forecast calls for Pharma operational growth of +9.2%/ 6.3%/ 5.1%/ 4.3% during 1Q – 4Q2018, and we now explicitly include the approval of apalutamide within our forecasts (drug model inside report).   Remicade erosion starting to become impactful and deteriorating pricing is likely affecting overall company gross margins: Mgmt noted that volumes for Remicade were generally steady during 4Q17, but this has come at the expense of pricing declines, which is a pure hit to product margins. Our best estimate is that the price erosion of Remicade negatively impacted overall company gross margins by – 30bps YoY during 4Q17." (1/24/2018)

Who are some of Johnson & Johnson's key competitors?

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

Mr. Alex Gorsky, Chairman & CEO (Age 58)
Mr. Dominic J. Caruso, Exec. VP & CFO (Age 60)
Dr. Paulus A. Stoffels, Exec. VP & Chief Scientific Officer (Age 56)
Mr. Joaquin Duato, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 55)
Ms. Sandra E. Peterson, Exec. VP & Group Worldwide Chairman (Age 59)

Has Johnson & Johnson been receiving favorable news coverage?

News stories about JNJ stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Johnson & Johnson earned a news sentiment score of 0.17 on Accern's scale. They also assigned news stories about the company an impact score of 46.36 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.54%), Northern Trust Corp (1.28%), Massachusetts Financial Services Co. MA (1.11%), Legal & General Group Plc (0.49%), Boston Partners (0.48%) and Fisher Asset Management LLC (0.47%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Which institutional investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Swiss National Bank, Legal & General Group Plc, Northern Trust Corp, FIL Ltd, Prudential Financial Inc., Barrow Hanley Mewhinney & Strauss LLC and California Public Employees Retirement System. Company insiders that have sold Johnson & Johnson company stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Which institutional investors are buying Johnson & Johnson stock?

JNJ stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Boston Partners, Summit Trail Advisors LLC, Flossbach Von Storch AG, Mackay Shields LLC, Schwartz Investment Counsel Inc., The Manufacturers Life Insurance Company and Thrivent Financial for Lutherans. View Insider Buying and Selling for Johnson & Johnson.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $121.47.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $331.20 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.

MarketBeat Community Rating for Johnson & Johnson (JNJ)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		555 (Vote Outperform)
Underperform Votes:		666 (Vote Underperform)
Total Votes:		1,221

MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Johnson & Johnson (NYSE:JNJ) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

20 Wall Street analysts have issued ratings and price targets for Johnson & Johnson in the last 12 months. Their average twelve-month price target is $143.0556, suggesting that the stock has a possible upside of 17.77%. The high price target for JNJ is $165.00 and the low price target for JNJ is $110.00. There are currently 4 sell ratings, 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.30	2.30	2.26	2.35
Ratings Breakdown:	4 Sell Rating(s) 6 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	4 Sell Rating(s) 6 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	4 Sell Rating(s) 6 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	4 Sell Rating(s) 5 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$143.0556	$143.0556	$145.7222	$143.7895
Price Target Upside:	17.77% upside	12.86% upside	2.74% upside	0.98% upside

Johnson & Johnson (NYSE:JNJ) Consensus Price Target History

Price Target History for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/23/2018	Citigroup	Lower Price Target	Neutral	$146.00 ➝ $134.00	Low
4/20/2018	Credit Suisse Group	Lower Price Target	Outperform ➝ Outperform	$154.00 ➝ $151.00	Low
4/18/2018	Wells Fargo & Co	Reiterated Rating	Outperform	$160.00 ➝ $150.00	High
4/18/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$145.00 ➝ $135.00	High
4/18/2018	Leerink Swann	Reiterated Rating	Outperform	$175.00 ➝ $160.00	High
4/18/2018	Deutsche Bank	Reiterated Rating	Buy		High
4/17/2018	Goldman Sachs Group	Set Price Target	Sell	$134.00	Low
4/13/2018	Jefferies Group	Set Price Target	Buy	$153.00	Low
4/10/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$148.00 ➝ $143.00	Low
1/24/2018	BTIG Research	Reiterated Rating	Sell	$110.00	Low
1/9/2018	Royal Bank of Canada	Reiterated Rating	Buy		Low
1/2/2018	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		Low
12/12/2017	BMO Capital Markets	Boost Price Target	Outperform	$161.00	Medium
10/18/2017	Barclays	Boost Price Target	Equal Weight	$140.00 ➝ $148.00	N/A
10/18/2017	Cowen	Reiterated Rating	Outperform	$147.00 ➝ $155.00	N/A
10/18/2017	Argus	Boost Price Target	Buy ➝ Positive	$145.00 ➝ $165.00	N/A
10/4/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$120.00	Low
9/30/2017	UBS	Reiterated Rating	Buy	$148.00	Low
7/21/2017	Alembic Global Advisors	Downgrade	Neutral ➝ Underweight		Low
7/21/2017	Atlantic Securities	Downgrade	Neutral ➝ Underweight	$113.00	Low
11/28/2016	Bank of America	Reiterated Rating	Hold	$126.00	N/A
10/23/2016	Societe Generale	Reiterated Rating	Hold	$116.00	N/A

(Data available from 5/26/2016 forward)

Johnson & Johnson (NYSE:JNJ) Earnings History and Estimates Chart

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Earnings Estimates

2018 EPS Consensus Estimate: $8.08
2019 EPS Consensus Estimate: $8.64

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$1.99	$2.00	$2.00
Q2 2018	1	$2.06	$2.06	$2.06
Q3 2018	1	$2.02	$2.02	$2.02
Q4 2018	1	$2.00	$2.00	$2.00
Q1 2019	1	$2.27	$2.27	$2.27
Q2 2019	1	$2.17	$2.17	$2.17
Q3 2019	1	$2.12	$2.12	$2.12
Q4 2019	1	$2.08	$2.08	$2.08

Johnson & Johnson (NYSE JNJ) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/17/2018		$2.06					N/A
4/17/2018	Q1 2018	$2.00	$2.06	$19.4975 billion	$20.0090 billion	View	N/A
1/23/2018	Q4 2017	$1.72	$1.74	$20.0797 billion	$20.1950 billion	View	Listen
10/17/2017	Q3 2017	$1.80	$1.90	$19.2910 billion	$19.65 billion	View	N/A
7/18/2017	Q2 2017	$1.79	$1.83	$18.9418 billion	$18.8390 billion	View	N/A
4/18/2017	Q1 17	$1.77	$1.83	$18.0198 billion	$17.7660 billion	View	N/A
1/24/2017	Q416	$1.56	$1.58	$18.28 billion	$18.10 billion	View	N/A
10/18/2016	Q316	$1.65	$1.68	$17.71 billion	$17.80 billion	View	Listen
7/19/2016	Q216	$1.68	$1.74	$17.98 billion	$18.50 billion	View	Listen
4/19/2016	Q116	$1.65	$1.68	$17.50 billion	$17.50 billion	View	Listen
1/26/2016	Q415	$1.42	$1.44	$17.88 billion	$17.80 billion	View	Listen
10/13/2015	Q315	$1.45	$1.49	$17.47 billion	$17.10 billion	View	Listen
7/14/2015	Q215	$1.69	$1.71	$17.76 billion	$17.80 billion	View	Listen
4/14/2015	Q115	$1.54	$1.56	$17.3077 billion	$17.3740 billion	View	Listen
1/20/2015	Q414	$1.25	$1.27	$18.59 billion	$18.30 billion	View	Listen
10/14/2014	Q314	$1.42	$1.50	$18.4139 billion	$18.50 billion	View	Listen
7/15/2014	Q214	$1.54	$1.66	$18.86 billion	$19.50 billion	View	N/A
4/15/2014	Q114	$1.48	$1.54	$18.00 billion	$18.10 billion	View	N/A
1/21/2014	Q413	$1.20	$1.24	$17.95 billion	$18.40 billion	View	N/A
10/15/2013	Q313	$1.32	$1.36	$17.46 billion	$17.60 billion	View	N/A
7/16/2013	Q2 2013	$1.39	$1.48	$17.71 billion	$17.90 billion	View	N/A
4/16/2013	Q1 2013	$1.41	$1.44	$17.46 billion	$17.50 billion	View	N/A
1/22/2013	Q4 2012	$1.17	$1.19	$17.67 billion	$17.60 billion	View	N/A
10/16/2012		$1.21	$1.25			View	N/A
7/17/2012		$1.29	$1.30			View	N/A
4/17/2012		$1.34	$1.37			View	N/A
1/24/2012		$1.09	$1.13			View	N/A
10/18/2011		$1.21	$1.24			View	N/A
7/19/2011		$1.24	$1.28			View	N/A
4/19/2011		$1.26	$1.35			View	N/A
1/25/2011		$1.03	$1.03			View	N/A
10/19/2010	Q3 2010	$1.15	$1.23			View	N/A
7/20/2010	Q2 2010	$1.21	$1.21			View	N/A
4/20/2010	Q1 2010	$1.27	$1.29			View	N/A
1/26/2010	Q4 2009	$0.97	$1.02			View	N/A
10/13/2009	Q3 2009	$1.13	$1.20			View	N/A
7/14/2009	Q2 2009	$1.12	$1.15			View	N/A
4/14/2009	Q1 2009	$1.21	$1.26			View	N/A
1/20/2009	Q4 2008	$0.92	$0.94			View	N/A
10/14/2008	Q3 2008	$1.11	$1.17			View	N/A
7/15/2008	Q2 2008	$1.13	$1.18			View	N/A
4/15/2008	Q1 2008	$1.20	$1.26			View	N/A
1/22/2008	Q4 2007	$0.86	$0.88			View	N/A

(Earnings results data provided by Zacks Investment Research)

Johnson & Johnson (NYSE:JNJ) Dividend Information

Johnson & Johnson pays an annual dividend of $3.36 per share, with a dividend yield of 2.77%. JNJ's next quarterly dividend payment will be made on Tuesday, June 12. The company has grown its dividend for the last 55 consecutive years and is increasing its dividend by an average of 6.40% each year. Johnson & Johnson pays out 46.03% of its earnings out as a dividend.

Next Dividend:	6/12/2018
Annual Dividend:	$3.36
Dividend Yield:	2.77%
Dividend Growth:	6.40% (3 Year Average)
Payout Ratio(s):	46.03% (Trailing 12 Months of Earnings) 41.33% (Based on This Year's Estimates) 38.89% (Based on Next Year's Estimates) 35.71% (Based on Cash Flow)
Track Record:	55 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/26/2018	quarterly	$0.90	2.81%	5/25/2018	5/29/2018	6/12/2018
1/2/2018	quarterly	$0.84	2.39%	2/26/2018	2/27/2018	3/13/2018
10/19/2017	quarterly	$0.84	2.37%	11/27/2017	11/28/2017	12/12/2017
7/17/2017	quarterly	$0.84	2.5%	8/25/2017	8/29/2017	9/12/2017
4/27/2017	quarterly	$0.84	2.72%	5/25/2017	5/30/2017	6/13/2017
1/3/2017	quarterly	$0.80	2.77%	2/24/2017	2/28/2017	3/14/2017
10/20/2016	quarterly	$0.80		11/18/2016	11/22/2016	12/6/2016
7/18/2016	quarterly	$0.80		8/19/2016	8/23/2016	9/6/2016
4/28/2016	quarterly	$0.80		5/20/2016	5/24/2016	6/7/2016
1/4/2016	quarterly	$0.75		2/19/2016	2/23/2016	3/8/2016
10/22/2015	quarterly	$0.75		11/20/2015	11/24/2015	12/8/2015
7/20/2015	quarterly	$0.75		8/21/2015	8/25/2015	9/8/2015
4/23/2015	quarterly	$0.75	2.97%	5/21/2015	5/26/2015	6/9/2015
1/5/2015	quarterly	$0.70	2.71%	2/20/2015	2/24/2015	3/10/2015
10/16/2014	quarterly	$0.70	2.89%	11/21/2014	11/25/2014	12/9/2014
7/21/2014	quarterly	$0.70	2.73%	8/22/2014	8/26/2014	9/9/2014
4/24/2014	quarterly	$0.70	2.81%	5/22/2014	5/27/2014	6/10/2014
1/2/2014	quarterly	$0.66	2.87%	2/21/2014	2/25/2014	3/11/2014
10/17/2013	quarterly	$0.66	2.88%	11/22/2013	11/26/2013	12/10/2013
7/15/2013	quarterly	$0.66	2.92%	8/23/2013	8/27/2013	9/10/2013
4/25/2013	quarterly	$0.66	3.1%	5/23/2013	5/28/2013	6/11/2013
1/2/2013	quarterly	$0.61	3.45%	2/22/2013	2/26/2013	3/12/2013

(Data available from 1/1/2013 forward)

Johnson & Johnson (NYSE JNJ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.22%
Institutional Ownership Percentage: 66.16%

Insider Trading History for Johnson & Johnson (NYSE:JNJ)

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/15/2018	Paulus Stoffels	VP	Sell	155,342	$129.86	$20,172,712.12	357,906
7/24/2017	Paulus Stoffels	VP	Sell	102,692	$133.14	$13,672,412.88	230,342
7/20/2017	Dominic J Caruso	VP	Sell	82,591	$136.72	$11,291,841.52	226,693
2/15/2017	Paulus Stoffels	VP	Sell	22,000	$117.29	$2,580,380.00	127,650
10/21/2016	Charles Prince	Director	Buy	875	$114.11	$99,846.25	26,520
7/26/2016	Dominic J Caruso	VP	Sell	41,146	$125.01	$5,143,661.46	157,819
7/22/2016	Ronald A Kapusta	CAO	Sell	2,935	$125.01	$366,904.35	28,660
6/7/2016	Gary J Pruden	VP	Sell	9,735	$116.03	$1,129,552.05	43,630
6/7/2016	Ronald A Kapusta	CAO	Sell	3,000	$115.79	$347,370.00	28,725
5/10/2016	Ronald A Kapusta	CAO	Sell	3,957	$114.77	$454,144.89	29,682
2/17/2016	Paulus Stoffels	insider	Sell	125,000	$102.43	$12,803,750.00	122,543
2/3/2016	Peter Fasolo	VP	Sell	151,385	$104.12	$15,762,206.20	37,735
10/23/2015	Ronald A. Kapusta	CAO	Sell	6,239	$99.68	$621,903.52	20,803
6/2/2015	Charles Prince	Director	Buy	2,500	$99.22	$248,050.00
4/28/2015	Paulus Stoffels	Insider	Sell	187,250	$100.73	$18,861,692.50
9/10/2014	James Cullen	Director	Sell	2,446	$104.12	$254,677.52
5/5/2014	Stephen Cosgrove	Insider	Sell	22,000	$100.05	$2,201,100.00	90,294
3/14/2014	Peter Fasolo	VP	Sell	6,824	$93.15	$635,655.60	15,647
8/14/2013	Stephen Cosgrove	Insider	Sell	17,200	$91.39	$1,571,908.00	88,159
8/5/2013	Michael Ullmann	VP	Sell	16,140	$93.68	$1,511,995.20	55,427
7/25/2013	Paulus Stoffels	Insider	Sell	45,440	$92.40	$4,198,656.00
7/18/2013	Dominic J Caruso	CFO	Sell	30,000	$90.31	$2,709,300.00
11/12/2012	James Cullen	Director	Sell	13,900	$69.70	$968,830.00

(Data available from 1/1/2013 forward)

Johnson & Johnson (NYSE JNJ) News Headlines

Source:

Date	Headline
	What Is Geron Corporation's Downside Risk? www.msn.com - May 25 at 8:07 AM
	If You Could Only Choose One Stock - Today's Editors' Picks seekingalpha.com - May 25 at 8:07 AM
	J&J Jury Asks Judge to Slap Cancer Warning Label on Baby Powder finance.yahoo.com - May 25 at 8:07 AM
	Jury recommends $25M in Johnson & Johnson lawsuit finance.yahoo.com - May 25 at 8:07 AM
	What Is Geron Corporation's Downside Risk? finance.yahoo.com - May 25 at 8:07 AM
	Johnson & Johnson (JNJ) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - May 25 at 5:20 AM
	Novartis Gets Approval for Remicade Biosimilar in Europe www.zacks.com - May 24 at 5:52 PM
	Willams-Sonoma, Deutsche Bank and Johnson & Johnson are the Yahoo Finance charts of the day. finance.yahoo.com - May 24 at 5:52 PM
	California Jury Delivers $25.75 Million Verdict in Asbestos Case Tying Johnson's Baby Powder to Mesothelioma www.bizjournals.com - May 24 at 5:52 PM
	J&J must pay $4 million in punitive damages in latest asbestos cancer trial www.cnbc.com - May 24 at 4:51 PM
	Jury awards $25M in Johnson & Johnson baby powder lawsuit marketbeat.com - May 24 at 4:33 PM
	Ex-Dividend Alert: Johnson & Johnson Boosted its Dividend by 7.1%; Will Trade Ex-Dividend on May 25, 2018 finance.yahoo.com - May 24 at 8:07 AM
	J&J Loses Second Talc-Asbestos Cancer Trial and Damages May Grow finance.yahoo.com - May 23 at 5:45 PM
	Chinese investors lead another monster round into this early cancer detection company finance.yahoo.com - May 22 at 8:10 AM
	Johnson & Johnson Vision Launches New Corporate Website www.prnewswire.com - May 21 at 5:17 PM
	It's Not as Bad as It Looks for Johnson & Johnson Stock investorplace.com - May 21 at 5:17 PM
	It’s Not as Bad as It Looks for Johnson & Johnson Stock finance.yahoo.com - May 21 at 5:17 PM
	How to Play the Long Side of Johnson & Johnson finance.yahoo.com - May 21 at 5:17 PM
	It’s Not as Bad as It Looks for Johnson & Johnson Stock investorplace.com - May 21 at 12:33 PM
	J&J Gets Rid Of Drug For Alzheimer's, But Remains Strong With Oncology Business seekingalpha.com - May 21 at 8:07 AM
	Today's Research Reports on Trending Tickers: Johnson & Johnson and The Procter & Gamble finance.yahoo.com - May 21 at 8:06 AM
	A Look into Roche Holding’s Performance in Q1 2018 finance.yahoo.com - May 21 at 8:06 AM
	ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer www.prnewswire.com - May 18 at 7:30 PM
	Macy's, Johnson & Johnson and T. Rowe Price are the Yahoo Finance charts of the day. finance.yahoo.com - May 18 at 6:14 PM
	Congo's Ebola not an international emergency, can be controlled -WHO finance.yahoo.com - May 18 at 6:14 PM
	Johnson & Johnson to Post FY2022 Earnings of $11.85 Per Share, Leerink Swann Forecasts (JNJ) www.americanbankingnews.com - May 18 at 8:43 AM
	Janssen to Present New Data in Urothelial, Haematologic and Prostate Cancers at ASCO 2018, including Best of ASCO Selections www.businesswire.com - May 18 at 8:13 AM
	Why J&J's Stock May Plunge 10% finance.yahoo.com - May 18 at 8:13 AM
	Zacks: Analysts Expect Johnson & Johnson (JNJ) Will Announce Quarterly Sales of $20.26 Billion www.americanbankingnews.com - May 18 at 2:00 AM
	Jim Cramer Shares His Thoughts On Johnson & Johnson, Nike And More finance.yahoo.com - May 17 at 7:12 PM
	Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report? finance.yahoo.com - May 17 at 7:12 PM
	How To Get Quality In The Core finance.yahoo.com - May 17 at 7:12 PM
	How Sensitive Is Johnson & Johnson To Its R&D Expense Change? www.forbes.com - May 17 at 3:51 PM
	Johnson & Johnson (JNJ) Consumer and Medical Devices Business Review - Brokers Conference Transcript seekingalpha.com - May 17 at 8:09 AM
	Johnson & Johnson (JNJ) Expected to Announce Earnings of $2.05 Per Share www.americanbankingnews.com - May 16 at 9:18 PM
	Jobs alert: Johnson & Johnson Institute in Lake Nona ready to hire managers finance.yahoo.com - May 16 at 5:56 PM
	J&J CEO warns of 'unintended consequences' of Trump's drug-price reduction plan www.cnbc.com - May 16 at 10:16 AM
	Johnson & Johnson to relaunch baby care line after its 20% sales decline www.msn.com - May 16 at 8:05 AM
	What Can I Expect To Make If I Invest In Johnson & Johnson Today? seekingalpha.com - May 16 at 8:05 AM
	Johnson & Johnson relaunches 124-year-old baby shampoo br... finance.yahoo.com - May 16 at 8:05 AM
	Stocks are set to fall at the open after Dow ends 8-day win streak finance.yahoo.com - May 16 at 8:05 AM
	Johnson & Johnson to relaunch baby-care line after its 20% sales decline finance.yahoo.com - May 16 at 8:05 AM
	Stocks making the biggest moves premarket: JNJ, SBUX, MMM, CHDN, ABAX, ROKU & more finance.yahoo.com - May 16 at 8:05 AM
	WHO deploys experimental vaccines to fight Ebola outbreak... finance.yahoo.com - May 15 at 5:57 PM
	Should You Buy Johnson & Johnson (NYSE:JNJ) Now? finance.yahoo.com - May 12 at 8:11 AM
	Trump's prescription to reduce drug prices takes small steps finance.yahoo.com - May 12 at 8:11 AM
	Few teeth in Trump's prescription to reduce drug prices marketbeat.com - May 11 at 6:30 PM
	Johnson & Johnson: Waiting On The Wave seekingalpha.com - May 11 at 6:13 PM
	NeuClone communique les résultats précliniques du candidat biosimilaire du Stelara® (ustekinumab) www.prnewswire.com - May 10 at 5:15 AM
	Johnson & Johnson Stock Looks Attractive on the Big Dip finance.yahoo.com - May 9 at 5:48 PM

Johnson & Johnson (NYSE:JNJ) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Johnson & Johnson (NYSE:JNJ) Income Statement, Balance Sheet and Cash Flow Statement

Johnson & Johnson (NYSE JNJ) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff